asciminib (Scemblix)

following a full submission assessed under the orphan equivalent medicine process:

asciminib (Scemblix®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and without a known T315I mutation.

In an open-label, phase III study, asciminib was associated with significantly higher major molecular response rates than another TKI in patients with Ph+ CML-CP who had received at least two previous TKIs and did not have a T315I mutation.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.